BioCentury on BioBusiness,
Product Discovery & Development
The Enbrel space
Monday, November 19, 2001
It's no secret that Immunex Corp. can't make enough of its Enbrel etanercept rheumatoid arthritis drug to meet demand. With every passing day, there is the potential that new patients will start taking the one competing anti-TNF drug, Johnson & Johnson's Remicade anti-TNF chimeric monoclonal antibody, which is approved for both RA and Crohn's disease.
IMNX also faces the possibility that it won't have ramped up production before a third compound is approved in the TNF space: Abbott Laboratories' D2E7 human anti-TNF antibody. ABT, which gained rights to D2E7 from Cambridge Antibody (LSE:CAT; CATG) through its acquisition of Knoll Pharmaceuticals in the first quarter of this year, plans to submit a BLA to the FDA in the second quarter of 2002 and hopes for approval in the first
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]